[0001] The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogcnesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof. Background [0002] A family of five closely relating enzymes have been linked to fibrotic disease and to metastatic cancer. The enzymes are related to lysyl oxidase (LOX), the first family member to be described and four closely related enzymes, LOX-likel (LOXLl), LOXL2, LOXL3, and LOXL4 ( agan H.M. and Li W., Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. ■/ Cell Biochem 2003; 88: 660-672). Lysyl oxidase isoenzymes are copper-dependent amine oxidases which initiate the covalent cross-linking of collagen and elastm. A major function of lysyl oxidase isoenzymes is to facilitate the cross-linking of collagen and elastin by the oxidative deamination of lysine and hydroxylysine amino acid side chains to aldehydes which spontaneously react with neighbouring residues. The resulting cross-linked strands contribute to extracellular matrix (ECM) stability. Lysyl oxidase activity is essential to maintain the tensile and elastic features of connective tissues of skeletal, pulmonary, and cardiovascular systems, among others. The biosynthesis of LOX is well understood; the protein is synthesized as a pre-proLOX that undergoes a series of post-translational modifications to yield a 50 kDa pro-enzyme which is secreted into the extracellular environment. For LOX and LOXLl proteolysis by bone morphogenctic protein-l (BMP- 1 ) and other procollagen C-proteinases releases the mature and active form. LOXL2, LOXL3 and LOXL4 contain scavenger receptor cysteine-rich protein domains and are directly secreted as active fonns. [0003] Lysyl oxidase isoenzymes belong to a larger group of amine oxidases which include flavin-dependent and copper-dependent oxidases which are described by the nature of the catalytic co-factor. Flavin-dependent enzymes include monoamine oxidasc-A (MAO-A), MAO-B, polyamine oxidase and lysine demethylase (LSD1), and the copper -dependent enzymes include semicarbazide sensitive amine oxidase (vascular adhesion protein- 1 , SSAO/VAP-1 ), retinal amine oxidase, diamine oxidase and the lysyl oxidase isoenzymes. The copper-dependent amine oxidases have a second co-factor which varies slightly from enzyme to enzyme. In SSAO/VAP-1 it is an oxidized tyrosine residue (TPQ, oxidized to a quinonc), whereas in the lysyl oxidase isoenzymes the TPQ has been further processed by addition of a neighboring lysine residue (to form LTQ); see f agan, H.M. and Li, W., Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003; 88: 660-672. [0004] Since lysyl oxidase isoenzymes exhibit different in vivo expression patterns it is likely that specific isoenzymes will have specific biological roles. Catalytically active forms of LOX have been identified in the cytosolic and nuclear compartments which suggest the existence of undefined roles of LOX in cellular homeostasis. Significant research is currently underway to define these roles. LOX itself, for example, plays a major role in epithelial -to-mesenchymal transition (EMT), cell migration, adhesion, transformation and gene regulation. Different patterns of LOX expression activity have been associated with distinct pathological processes including fibrotic diseases, Alzheimer's disease and other neurodegenerative processes, as well as tumour progression and metastasis. See, for example, Woznick, A.R., et al. Lysyl oxidase expression in bronchogenic carcinoma. Am J Surg 2005; 189: 297-301. Catalytically active forms of LOXL2 can be also found in the nucleus (J Biol Chem. 2() 13;288: 30000-30008) and can deaminate lysine 4 in histone H3 (Mo! Cell 2012 46: 369-376). [0005] Directed replacement of dead or damaged cells with connective tissue after injury represents a survival mechanism that is conserved throughout evolution and appears to be most pronounced in humans serv ing a valuable role following traumatic injury, infection or diseases. Progressive scarring can occur following more chronic and/or repeated injuries that causes impaired function to parts or all of the affected organ. A variety of causes, such as chronic infections, chronic exposure to alcohol and other toxins, autoimmune and allergic reactions or radio- and chemotherapy can all lead to fibrosis. This pathological process, therefore, can occur in almost any organ or tissue of the body and, typically, results from situations persisting for several weeks or months in which inflammation, tissue destruction and repair occur simultaneously. In this setting, fibrosis most frequently affects the lungs, liver, skin and kidneys. [0006] Liver fibrosis occurs as a complication of haemochromatosis, Wilson's disease, alcoholism, schistosomiasis, viral hepatitis, bile duct obstruction, exposure to toxins and metabolic disorders. Liver fibrosis is characterized by the accumulation of extracellular matrix that can be distinguished qualitatively from that in normal liver. This fibrosis can progress to cirrhosis, liver failure, cancer and eventually death. This is reviewed in agan, H.M. Lysyl oxidase: Mechanism, regulation and relationship to liver fibrosis. Pathology - Research and Practice 1994; 190: 910-919. [0007] Fibrotic tissues can accumulate in the heart and blood vessels as a result of hypertension, hypertensive heart disease, atherosclerosis and myocardial infarction where the accumulation of extracellular matrix or fibrotic deposition results in stiffening of the vasculature and stiffening of the cardiac tissue itself. See Lopez, B., et al. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol 2010; 299: H 1-H9. [0008] A strong association between fibrosis and increased lysyl oxidase activity has been demonstrated. For example, in experimental hepatic fibrosis in rat (Siegel, R.C., Chen, K.H. and Acquiar, J.M, Biochemical and immunochemical study of lysyl oxidase in experimental hepatic fibrosis in the rat. Proc. Natl. Acad. Sci. USA 1978; 75: 2945-2949), in models of lung fibrosis (Counts, D.F., et al, Collagen lysyl oxidase activity in the lung decreases during bleomycin-induced lung fibrosis. J Pharmacol Exp l ' iter 1981; 219: 675-678) in arterial fibrosis (Kagan, H.M., Raghavan, J. and Hollander, W., Changes in aortic lysyl oxidase activity in diet-induced atherosclerosis in the rabbit. Arteriosclerosis 1981 ; 1 : 287-291.), in dermal fibrosis (Chanoki, M., et al., Increased expression of lysyl oxidase in skin with scleroderma. Br J Dermatol 1995; 133: 710-715) and in adriamycin-induced kidney fibrosis in rat (Di Donato, A., et al., Lysyl oxidase expression and collagen cross-linking during chronic adriamycin nephropathy. Nephron 1997; 76: 192-200). Of these experimental models of human disease, the most striking increases in enzyme activity are seen in the rat model of CCl4-induced liver fibrosis. In these studies, the low level of enzyme activity in the healthy liver increased 15- to 30-fold in fibrotic livers. The rationale for the consistent and strong inhibition of fibrosis by lysyl oxidase isoenzyme blockers is that the lack of cross-linking activity renders the collagen susceptible to matrix metalloproteinases and causes degradation. Hence, any type of fibrosis should be reversed by treatment with lysyl oxidase isoenzyme inhibitors. In humans, there is also a significant association between lysyl oxidase activity measured in the plasma and liver fibrosis progression. Lysyl oxidase activity level is normally negligible in the serum of healthy subjects, but significantly increased in chronic active hepatitis and even more in cirrhosis, therefore lysyl oxidase might serve as a marker of internal fibrosis. [0009] BAPN (β-aminopropionitrile) is a widely used, nonselective lysyl oxidase inhibitor. Since the 1960s BAPN has been used in animal studies (mainly rat, mouse and hamster) and has been efficacious in reducing collagen content in various models (eg. CC14, bleomycin, quartz) and tissues (eg. liver, lung and dermis). See Kagan, H.M. and Li, W., Lysyl oxidase: Properties, specificity and biological roles inside and outside of the cell. J Cell Biochem 2003; 88: 660-672. [0010] Lysyl oxidase isoenzymes are highly regulated by Hypoxia-Induced Factor la (HIF- l a) and TGF-β, the two most prominent growth factor that cause fibrosis (Halberg et al., Hypoxia-inducible factor l a induces fibrosis and insulin resistance in white adipose tissue. Cell Biol 2009; 29: 4467-4483). Collagen cross linking occurs in every type of fibrosis, hence a lysyl oxidase isoenzyme inhibitor could be used in idiopathic pulmonary fibrosis, scleroderma, kidney or liver fibrosis. Lysyl oxidase isoenzymes are not only involved in the cross-linking of elastin and collagen during wound healing and fibrosis but also regulate cell movement and signal transduction. Its intracellular and intranuclear function is associated with gene regulation and can lead to tumorgenesis and tumor progression (Siddikiuzzaman, Grace, V.M and Guruvayoorappan, C, Lysyl oxidase: a potential target for cancer therapy. Inflammapharmacol 201 1 ; 19: 1 17- 129). Both down and upregulation of lysyl oxidase isoenzymes in tumour tissues and cancer cell lines have been described, suggesting a dual role for lysyl oxidase isoenzymes and LOX pro-peptide as a metastasis promoter gene as well as a tumour suppressor gene. [0011] To date, an increase in lysyl oxidase isoenzymes mRNA and/or protein has been observed in breast, CNS cancer cell lines, head and neck squamous cell, prostatic, clear cell renal cell and lung carcinomas, and in melanoma and osteosarcoma cell lines. Statistically significant clinical correlations between lysyl oxidase isoenzymes expression and tumor progression have been observed in breast, head and neck squamous cell, prostatic and clear cell renal cell carcinomas. The role of lysyl oxidase isoenzymes in tumor progression has been most extensively studied in breast cancer using in vitro models of migration/invasion and in in vivo tumorgenesis and metastasis mouse models. Increased lysyl oxidase isoenzymes expression was found in hypoxic patients, and was associated with negative estrogen receptor status (ER-), decreased overall survival in ER- patients and node-negative patients who did not receive adjuvant systemic treatment, as well as shorter metastasis-free survival in ER- patients and node negative patients. Lysyl oxidase isoenzymes mRNA was demonstrated to be up-regulated in invasive and metastatic cell lines (MDA-MB-23 1 and Hs578T), as well as in more aggressive breast cancer cell lines and distant metastatic tissues compared with primary cancer tissues. [0012] In head and neck squamous cell carcinomas, increased lysyl oxidase isoenzyme expression was found in association with CA-IX, a marker of hypoxia, and was associated with decreased cancer specific survival, decreased overall survival and lower metastasis-free survival. In oral squamous cell carcinoma, lysyl oxidase isoenzyme mRNA expression was upregulated compared to normal mucosa. [0013] Gene expression profiling of gliomas identified over-expressed lysyl oxidase isoenzyme as part of a molecular signature indicative of invasion, and associated with higher-grade tumors that are strongly correlated with poor patient survival. Lysyl oxidase isoenzyme protein expression was increased in glioblastoma and astrocytoma tissues, and in invasive U343 and U251 cultured astrocytoma cells. [0014] In tissues, lysyl oxidase isoenzyme mRNA was upregulated in prostate cancer compared to benign prostatic hypertrophy, correlated with Gleason score, and associated with both high grade and short time to recurrence (Stewart, G.D., et al., Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter- 1 expression correlate with Gleason score. Oncol Rep 2008; 20: 1561-1567). [0015] Up-regulation of lysyl oxidase isoenzyme mRNA expression was detected in renal cell carcinoma (RCC) cell lines and tissues. Clear cell RCC also demonstrated lysyl oxidase isoenzyme up-regulation. Indeed, LOX over expression appeared preferentially in clear cell RCC compared to mixed clear and granular, granular, oxyphil, tubulopapillary and chromophobe RCC/ontocytomas. In clear cell RCC, smoking was associated with allelic imbalances at chromosome 5q23. 1 , where the LOX gene is localized, and may involve duplication of the gene. [0016] SiHa cervical cancer cells demonstrated increased im-asion in vitro under hypoxic/anoxic conditions; this was repressed by inhibition of extracellular catalytically active lysyl oxidase activity by treatment with BAPN as well as LOX antisense oligos, LOX antibody, LOX shRNA or an extracellular copper chelator. [0017] The scientific and patent literature describes small molecule inhibitors of lysyl oxidase isoenzymes and antibodies of LOX and LOXL2 with therapeutic effects in animal models of fibrosis and cancer metastasis. Some known MAO inhibitors also are reported to inhibit lysyl oxidase isoenzyme (e.g., the MAO-B inhibitor Mofegiline illustrated below). This inhibitor is a member of the haloallylamine family of MAO inhibitors; the halogen in Mofegiline is fluorine. Fluoroallylamine inhibitors are described in US Patent No. 4,454, 158. There are issued patents claiming fluoroallylamines and chloroallylamines, for example MDL72274 (illustrated below) as inhibitors of lysyl oxidase (US Patents 4,943,593; 4,965,288; 5,021 ,456; 5,059,714; 5, 182,297; 5,252,608). Many of the compounds claimed in these patents are also reported to be potent MAO-B and SSAO/VAP- 1 inhibitors. Mofegiline MDL72274. [0018] Additional fluoroallylamine inhibitors are described US Patent 4,699,928. Other examples structurally related to Mofegiline can be found in WO 2007/120528. [0019] WO 2009/066152 discloses a family of 3-substituted 3-haloallylamines that are inhibitors of SSAO/VAP-1 useful as treatment for a variety of indications, including inflammatory disease. None of these documents specifically disclose the fluoroallylamine compounds of formula (I) according to the present invention. [0020] Antibodies to LOX and LOXL2 have been disclosed in US 2009/0053224 with methods to diagnostic and therapeutic applications. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state: US 201 1/0044907. Summary [0021] The present invention provides substituted fluoroallylamine compounds that inhibit lysyl oxidase (LOX), lysyl oxidase-like2 (LOXL2) and other lysyl oxidase isoenzymes. Surprisingly, modification of 3-substituted-3-fluoroallylamine structures described previously has led to the discovery of novel compounds that are potent inhibitors of the human LOX and LOXL isoenzymes. Furthermore, certain of these novel compounds also selectively inhibit certain LOX and LOXL isoenzymes with respect to the other enzymes in the amine oxidase family. [0022] A first aspect of the invention provides for a compound of Fonnula I: Formula I or a stereoisomer, pharmaceutically acceptable salt, polymorphic form, solvate, tautomeric form or prodrug thereof; wherein: a is N or CR3; b is N or CR4; c is N or CR5; d is N or CR6; and from 0 to 2 of a, b, c and d are N; X is 0 or -(CHR7)m- m is 1 or 2; R1 is selected from the group consisting of hydrogen, halogen, Ci_6alkyl, C3_7cycloalkyl, -0-d_6alkyl, -0-C3-7cycloalkyl, -C(0)OR8, -C(0)NR9R10 and -NR9C(0)R" ; wherein each Q. 6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C,_3alkyl, -0-C,_3alkyl, -CF3, -CH2CF3, and -0-CF3; R2 is aryl or heteroaryl; wherein each R2 is optionally substituted by one or more R12; R3, R4, R5 and R6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, Ci_5alkyl, C3.7cycloalkyl, -0-Ci_6alkyl, -0-C3_7cycloalkyl, -CN, -N02, -NR R10, -C(0)OR8, -C(0)NR9R10, -NR9C(0)Ru, -S(02)NR9R10, -NR9S(02)Rn, -S(0)RH, -S(02)Ru, tetrazole and oxadiazole; wherein each C^alkyl is a straight or branched chain alkyl; and wherein each d_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3; each R' is independently selected from the group consisting of hydrogen, hydroxyl and C1-3alkyl; R8 is selected from the group consisting of hydrogen, d_6alkyl, and C3_7cycloalkyl; wherein each Cj_6alkyl is a straight or branched chain alkyl; and wherein each C^alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_ alkyl, -0-Ci_ alkyl, -CF3, -CH2CF3, and -0-CF3; R9 and R10 are independently selected from the group consisting of hydrogen, C]-6alkyl and C3_7cycloalkyl; wherein each Chalk 1 is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C,_3alkyl, -0-CK alkyl, -CF3, -CH2CF3, and -0-CF3; or R9 and R10 when attached to the same nitrogen atom arc combined to form a 3- to 7-membercd ring having from 0 to 2 additional heteroatoms as ring members; R11 is selected from the group consisting of Ci_6alkyl and C3_7cycloalkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -Cj.3alkyl, -0-CV3alkyl, -CF3, -CH2CF3, and -0-CF3; and R12 is selected from the group consisting of halogen, C^alkyl, -O-CVcalkyl, -S-Ci-salkyl, C3.7cycloalkyl, -0-C3_7cycloalkyl, -C(0)OR8, -C(0)NR9R10, -NR9C(0)Ru , -S(02)NR9R10, -NR9S(02)Rn, -S(0)Ru and -S(02)RH; wherein each C,.6alkyl is a straight or branched chain alkyl; and wherein each C]-6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -Ci_3alkyl, -0-C1-3alkyl, -CF3, -CH2CF3, and -0-CF3. [0023] A second aspect of the invention provides for a pharmaceutical composition comprising a compound according to the first aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and at least one pharmaceutically acceptable excipient, carrier or diluent. [0024] A third aspect of the invention provides for a method of inhibiting the amine oxidase activity of LOX, LOXLl , LOXL2, LOXL3 and LOXL4 in a subject in need thereof, comprising administering to the subject an effective amount of a compound according to the first aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition according to the second aspect of the invention. [0025] A fourth aspect of the invention provides for a method of treating a condition associated with LOX, LOXL l , LOXL2, LOXL3 and LOXL4 protein, comprising administering to a subject in need thereof a therapeutically effective amount of compound according to the first aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition according to the second aspect of the invention. [0026] A fifth aspect of the invention provides for use of a compound according to the first aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the manufacture of a medicament for treating a condition associated with LOX, LOXL l , LOXL2, LOXL3 and LOXL4 protein. [0027] A sixth aspect of the invention provides for a compound according to the first aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use in treating a condition associated with LOX, LOXL 1 , LOXL2, LOXL3 and LOXL4 protein. [0028] In one embodiment of the methods and uses of the present invention the condition is selected from a liver disorder, kidney disorder, cardiovascular disease, fibrosis, cancer and angiogenesis. [0029] Contemplated herein is combination therapy in which the methods further comprise co-administering additional therapeutic agents that are used for the treatment of liver disorders, kidney disorders, cardiovascular diseases, cancer, fibrosis, angiogenesis and inflammation. Definitions [0030] The following are some definitions that may be helpful in understanding the description of the present invention. These are intended as general definitions and should in no way limit the scope of the present invention to those terms alone, but are put forth for a better understanding of the following description. [0031] Unless the context requires otherwise or specifically states to the contrary, integers, steps, or elements of the invention recited herein as singular integers, steps or elements clearly encompass both singular and plural forms of the recited integers, steps or elements. [0032] Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated step or element or integer or group of steps or elements or integers, but not the exclusion of any other step or element or integer or group of elements or integers. Thus, in the context of this specification, the term "comprising" means "including principally, but not necessarily solely". [0033] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features. [0034] As used herein, the term "alkyl" includes within its meaning monovalent ("alkyl") and divalent ("alkylene") straight chain or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms, e.g., 1 , 2, 3, 4, 5 or 6 carbon atoms. The straight chain or branched alkyl group is attached at any available point to produce a stable compound. For example, the term alkyl includes, but is not limited to, methyl, ethyl, 1 -propyl, isopropyl, 1 -butyl, 2-butyl, isobutyl, tert-butyl, amyl, 1,2-dimethylpropyl, 1 , 1 -dimethylpropyl, pentyl, isopentyl, hexyl, 4-methylpentyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1 ,3-dimethylbutyl, 1,2,2-trimethylpropyl, 1 , 1 ,2-trimethylpropyl, and the like. [0035] The term "alkoxy" or "alkyloxy" as used herein refers to straight chain or branched alkyloxy (i.e, O-alkyl) groups, wherein alkyl is as defined above. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, and isopropoxy. [0036] The term "cycloalkyl" as used herein includes within its meaning monovalent ("cycloalkyl") and divalent ("cycloalkylene") saturated, monocyclic, bicyclic, polycyclic or fused analogs. In the context of the present disclosure the cycloalkyl group may have from 3 to 10 carbon atoms. In the context of the present disclosure the cycloalkyl group may also have from 3 to 7 carbon atoms. A fused analog of a cycloalkyl means a monocyclic ring fused to an aryl or heteroaryl group in which the point of attachment is on the non-aromatic portion. Examples of cycloalkyl and fused analogs thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, adamantyl and the like. [0037] The term "aryl" or variants such as "arylene" as used herein refers to monovalent ("aryl") and divalent ("arylene") single, polynuclear, conjugated and fused analogs of aromatic hydrocarbons having from 6 to 10 carbon atoms. A fused analog of aryl means an aryl group fused to a monocyclic cycloalkyl or monocyclic heterocyclyl group in which the point of attachment is on the aromatic portion. Examples of aryl and fused analogs thereof include phenyl, naphthyl, indanyl, indenyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, 1 ,3-benzodioxolyl, 1 ,4-benzodioxanyl, and the like. A "substituted aryl" is an aryl that is independently substituted, with one or more, preferably 1 , 2 or 3 substituents, attached at any available atom to produce a stable compound. [0038] The term "alkylaryl" as used herein, includes within its meaning monovalent ("aryl") and divalent ("arylene"), single, polynuclear, conjugated and fused aromatic hydrocarbon radicals attached to divalent, saturated, straight or branched chain alkylene radicals. Examples of alkylaryl groups include benzyl. [0039] The term "heteroaryl" and variants such as "heteroaromatic group" or "heteroarylene" as used herein, includes within its meaning monovalent ("heteroaryl") and divalent ("heteroarylene"), single, polynuclear, conjugated and fused heteroaromatic radicals having fi-om 5 to 10 atoms, wherein 1 to 4 ring atoms, or 1 to 2 ring atoms are heteroatoms independently selected from O, N, NH and S. Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxidc of a tertiary ring nitrogen. A carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable compound is produced. The heteroaromatic group may be Cs_8 heteroaromatic. A fused analog of heteroaryl means a heteroaryl group fused to a monocyclic cycloalkyl or monocyclic heterocyclyl group in which the point of attachment is on the aromatic portion. Examples of heteroaryl groups and fused analogs thereof include pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, triazinyl, thienyl, benzoxazolyl, bcnzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo(2,3-b)pyridyl, quinolyl, indolyl, isoquinolyl, pyrimidinyl, pyridazinyl, pyrazinyl, 2,2'-bipyridyl, phenanthrolinyl, quinolinyl, isoquinolinyl, imidazolinyl, thiazolinyl, pyrrolyl, furanyl, thiophenyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, and the like. "Nitrogen containing heteroaryl" refers to heteroaryl wherein any heteroatoms are N. A "substituted heteroaryl" is a heteroaryl that is independently substituted, with one or more, preferably 1 , 2 or 3 substituents, attached at any available atom to produce a stable compound. [0040] The term "heterocyclyl" and variants such as "heterocycloalkyl" as used herein, includes within its meaning monovalent ("heterocyclyl") and divalent ("heterocyclylene"), saturated, monocyclic, bicyclic, polycyclic or fused hydrocarbon radicals having from 3 to 10 ring atoms, wherein from 1 to 5, or from 1 to 3, ring atoms are heteroatoms independently selected from O, N, NH, or S, in which the point of attachment may be carbon or nitrogen. A fused analog of heterocyclyl means a monocyclic heterocycle fused to an aryl or heteroaryl group in which the point of attachment is on the non-aromatic portion. The heterocyclyl group may be C3_8 heterocyclyl. The heterocycloalkyl group may be C3.6 heterocyclyl. The heterocyclyl group may be C3-5 heterocyclyl. Examples of heterocyclyl groups and fused analogs thereof include aziridinyl, pyrrolidinyl, thiazolidinyl, piperidinyl, piperazinyl, imidazolidinyl, 2,3-dihydrofuro(2,3-b)pyridyl, benzoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl, quinuclidinyl, azetidinyl, morpholinyl, tetrahydrothiophenyl, tetrahydrofuranyl, tetrahydropyranyl, and the like. The term also includes partially unsaturated monocyclic rings that are not aromatic, such as 2- or 4-pyridones attached through the nitrogen or N-substituted uracils. [0041] The term "halogen" or variants such as "halide" or "halo" as used herein refers to fluorine, chlorine, bromine and iodine. [0042] The term "heteroatom" or variants such as "hetero-" or "heterogroup" as used herein refers to O, N, NH and S. [0043] In general, "substituted" refers to an organic group as defined herein (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms. Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom. Thus, a substituted group will be substituted with one or more substituents, unless otherwise specified. In some embodiments, a substituted group is substituted with 1 , 2, 3, 4, 5, or 6 substituents. [0044] The term "optionally substituted" as used herein means the group to which this term refers may be unsubstituted, or may be substituted with one or more groups independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, halo, haloalkyl, haloalkynyl, hydroxyl, hydroxyalkyl, alkoxy, thioalkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, N02, NH(alkyl), N(alkyl)2, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroheterocyclyl, alkylamino, dialkylamino, alkenylamine, alkynylamino, acyl, alkenoyl, alkynoyl, acylamino, diacylamino, acyloxy, alkylsulfonyloxy, heterocycloxy, heterocycloamino, haloheterocycloalkyl, alkylsulfenyl, alkylcarbonyloxy, alkylthio, acylthio, phosphorus-containing groups such as phosphono and phosphinyl, aryl, heteroaryl, alkylaryl, aralkyl, alkylheteroaryl, cyano, cyanatc, isocyanate, C02H, C02alkyl, C(0)NH2, -C(0)NH(alkyl), and -C(0)N(alkyl)2. Preferred substituents include halogen, C Qalkyl, C2-C6alkenyl, Ci-C6haloalkyl, C]-C6alkoxy, hydroxy Q alkyl, C3-C6cycloalkyl, C(0)H, C(0)OH, NHC(0)H, NHC(0)C1-C4alkyl, C(0)Ci-C4alkyl, NH2, NHd-C4alkyl, N(C C4alkyl)2, N02, OH and CN. Particularly preferred substituents include C^alkyl, C^alkoxy, halogen, OH, hydroxy(Ci_3)alkyl (e.g. CH2OH), C(0)Ci-C4alkyl (e.g. C(0)CH3), and Ci_3haloalkyl (e.g. CF3, CH2CF3). Further preferred optional substituents include halogen, -OH, -SH, -Ci_3alkyl, -0-G_3alkyl, -CF3, -CH2CF3, and -0-CF3. [0045] The term "bioisostere" refers to a compound resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms. The objective of a bioiosteric replacement is to create a new compound with similar biological properties to the parent compound. The bioisosteric replacement may be physiochemically or topologically based. [0046] The present invention includes within its scope all stcreoisomeric and isomeric forms of the compounds disclosed herein, including all diastereomeric isomers, racemates, enantiomers and mixtures thereof. It is also understood that the compounds described by Formula I may be present as E and Z isomers, also known as cis and trans isomers. Thus, the present disclosure should be understood to include, for example, E, Z, cis, trans, (R), (S), (L), (D), (+), and/or (-) forms of the compounds, as appropriate in each case. Where a structure has no specific stereoisomerism indicated, it should be understood that any and all possible isomers are encompassed. Compounds of the present invention embrace all conformational isomers. Compounds of the present invention may also exist in one or more tautomeric forms, including both single tautomers and mixtures of tautomers. Also included in the scope of the present invention are all polymorphs and crystal forms of the compounds disclosed herein. [0047] The present invention includes within its scope isotopes of different atoms. Any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Thus, the present disclosure should be understood to include deuterium and tritium isotopes of hydrogen. [0048] All references cited in this application are specifically incorporated by cross-reference in their entirety. Reference to any such documents should not be construed as an admission that the document forms part of the common general knowledge or is prior art. [0049] In the context of this specification the term "administering" and variations of that term including "administer" and "administration", includes contacting, applying, delivering or providing a compound or composition of the invention to an organism, or a surface by any appropriate means. In the context of this specification, the term "treatment", refers to any and all uses which remedy a disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of disease or other undesirable symptoms in any way whatsoever. [0050] In the context of this specification the term "effective amount" includes within its meaning a sufficient but non-toxic amount of a compound or composition of the invention to provide a desired effect. Thus, the term "therapeutically effective amount" includes within its meaning a sufficient but non-toxic amount of a compound or composition of the invention to provide the desired therapeutic effect. The exact amount required will vary from subject to subject depending on factors such as the species being treated, the sex, age and general condition of the subject, the severity of the condition being treated, the particular agent being administered, the mode of administration, and so forth. Thus, it is not possible to specify an exact "effective amount". However, for any given case, an appropriate "effective amount" may be determined by one of ordinary skill in the art using only routine experimentation. Brief Description of the Figures [0051] Figure 1 shows the ability of Compound 22 to reduce fibrosis in a rat model of liver fibrosis. [0052] Figure 2 shows the ability of Compound 22 to reduce fibrosis in a mouse model of steptozotocin and high fat diet induced liver fibrosis. [0053] Figure 3 shows the ability of Compound 22 to reduce collagen cross-link formation in an in vitro fibroblastic foci model of idiopathic pulmonary fibrosis (1PF). Detailed Description [0054] The present invention relates to substituted fluoroallylamine derivatives which may inhibit lysyl oxidase (LOX), lysyl oxidase-like2 (LOXL2) and other lysyl oxidase isoenzymes. In particular the present invention relates to substituted fluoroallylamine derivatives with an indole or azaindole group. [0055] In particular the present invention relates to compounds of Formula I: Formula I or a stereoisomer, pharmaceutically acceptable salt, polymorphic form, solvate, tautomeric form or prodrug thereof; wherein: a is N or CR3; b is N or CR4; c is N or CR5; d is N or CR6; and from 0 to 2 of a, b, c and d are N; X is 0 or -(CHR7)m- m is 1 or 2; R1 is selected from the group consisting of hydrogen, halogen, Ci_6alkyl, C3_7cycloalkyl, -0-d_6alkyl, -0-C3_7cycloalkyl, -C(0)OR8, -C(0)NR9RU) and -NR9C(0)Rn ; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each C ^alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C,.3alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -0-CF3; R2 is aryl or heteroaryl; wherein each R2 is optionally substituted by one or more R12; R3, R4, R5 and R6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, Ci_5alkyl, C3.7cycloalkyl, -0-Ci.6alkyl, -0-C3_7cycloalkyl, -CN, -N02, -NR R10, -C(0)OR8, -C(0)NR9R10, -NR9C(0)Ru, -S(02)NR9R10, -NR9S(02)Rn, -S(0)RH, -S(02)Ru, tetrazole and oxadiazole; wherein each C^alkyl is a straight or branched chain alkyl; and wherein each d_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C^alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3; each R' is independently selected from the group consisting of hydrogen, hydroxyl and C1-3alkyl; R8 is selected from the group consisting of hydrogen, d_6alkyl, and C3_7cycloalkyl; wherein each Cj_6alkyl is a straight or branched chain alkyl; and wherein each C^alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-Ci_ alkyl, -CF3, -CH2CF3, and -0-CF3; R9 and R10 are independently selected from the group consisting of hydrogen, C]-6alkyl and C3_7cycloalkyl; wherein each Chalk 1 is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C,_3alkyl, -0-CK alkyl, -CF3, -CH2CF3, and -0-CF3; or R9 and R10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members; R11 is selected from the group consisting of Ci_6alkyl and C3_7cycloalkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -Cj.3alkyl, -0-C1-3alkyl, -CF3, -CH2CF3, and -0-CF3; and R12 is selected from the group consisting of halogen, C^alkyl, -0-Ci_6alkyl, -S-Ci-ealkyl, C3.7cycloalkyl, -0-C3_7cycloalkyl, -C(0)OR8, -C(0)NR9R10, -NR9C(0)Ru, -S(02)NR9R10, -NR9S(02)Rn, -S(0)Ru and -S(02)RH; wherein each CI -6alkyl is a straight or branched chain alkyl; and wherein each C]-6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -Ci_3alkyl, -O-d.jalkyl, -CF3, -CH2CF3, and -0-CF3 [0056] In one embodiment of compounds of the present invention none of a, b, c and d is N and a is CR3, b is CR4, c is CR ' and d is CR6 so that the compounds of Formula I are indole derivatives. In a further embodiment of compounds of the present invention one of a, b, c and d is N so that the compounds of Formula I are azaindole derivatives. In another embodiment of compounds of the present invention a is N, b is CR4, c is CR5 and d is CR6. In a further embodiment of compounds of the present invention a is CR3, b is N, c is CR3 and d is CR6. In another embodiment of compounds of the present invention a is CR3, b is CR4, c is N and d is CR6. In a still further embodiment of compounds of the present invention a is CR', b is CR4, c is CR5 and d is N. In another embodiment of compounds of the present invention two of a, b, c and d arc N. In a further embodiment of compounds of the present invention a is CR3, b is CR4, c is N and d is N. In another embodiment of compounds of the present invention a is CR3, b is N, c is CR5 and d is N. In another embodiment of compounds of the present invention a is N, b is CR4, c is N and d is CR6. In a further embodiment of compounds of the present invention a is CR3, b is N, c is N and d is CR6. In another embodiment of compounds of the present invention a is N, b is N, c is CR5 and d is CR6. In a further embodiment of compounds of the present invention a is N, b is CR4, c is CR5 and d is N. [0057] In one embodiment of compounds of the present invention X is O or -(CHR7)m-; m is 1 or 2; and each R7 is independently selected from the group consisting of hydrogen, hydroxyl and Ci_3alkyl. In another embodiment of compounds of the present invention X is O. In another embodiment of compounds of the present invention X is -(CHR7)m-, m is 1 and R7 is selected from the group consisting of hydrogen, hydroxyl and Ci_3alkyl. In a further embodiment of compounds of the present invention X is -(CHR7)m-, m is 1 and R7 is hydrogen so that X is -CH2-. In a further embodiment of compounds of the present invention X is -(CHR7)m-, m is 1 and R7 is hydroxyl so that X is -CHOH-. In another embodiment of compounds of the present invention X is -(CHRV, m is 2 and R is selected from the group consisting of hydrogen, hydroxyl and C1-3alkyl. In a further embodiment of compounds of the present invention X is -(CHR7)m-, m is 2 and each R7 is hydrogen so that X is -CH2CH2-. [0058] In one embodiment of compounds of the present invention Rl is selected from the group consisting of hydrogen, halogen, C]_6alkyl, C3_7cycloalkyl, -0-C].6alkyl, -0-C3_7cycloalkyl, -C(0)OR8, -C(0)NR9R'0 and -NR9C(0)RJ ' ; wherein each d^alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -O-CF3. In another embodiment of compounds of the present invention each Rl is independently selected from the group consisting of hydrogen, halogen, Ci_6alkyl, and -C(0)NR9R10; wherein each C]_6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -0-Ci_3alkyl, -CF3, -CH2CF3, and -O-CF3. In a further embodiment of compounds of the present invention each R1 is independently selected from the group consisting of hydrogen, halogen, C].3alkyl, and -C(0)N(CH3)2; wherein each C]_3alkyl is a straight or branched chain alkyl; and wherein each Ci_3alkyl is optionally substituted by one or more substituents selected from the group consisting of halogen and -OH. In one embodiment of compounds of the present invention R1 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, 1 -hydroxyethyl, 2-hydroxyisopropyl, chloro and -C(0)N(CH3)2. In another embodiment of compounds of the present invention R1 is selected from the group consisting of hydrogen, methyl and isopropyl. In a further embodiment of compounds of the present invention R1 is methyl. In another embodiment of compounds of the present invention R1 is isopropyl. [0059] In one embodiment of compounds of the present invention R2 is aryl or heteroaryl where each R2 is optionally substituted by one or more R12. In another embodiment of compounds of the present invention R2 is aryl optionally substituted by one or more R12. In another embodiment of compounds of the present invention is phenyl substituted by one R12. In a further embodiment of compounds of the present invention R2 is heteroaryl substituted by one or more R12. In another embodiment of compounds of the present invention R2 is heteroaryl substituted by one or more R12. In a further embodiment of compounds of the present invention R2 is selected from the group consisting of phenyl 1 ,3-benzodioxolyl 2-pyridinyl 3-pyridinyl N , 4-pyridinyl and 5-pyrimidinyl N ; wherein each R2 is optionally substituted by one or more R12. In another embodiment of compounds of the present invention R" is phenyl substituted by one R12 or 1 ,3-benzodioxolyl jn another embodiment of compounds of the present invention R2 is a heteroaryl selected from the group consisting of 2-pyridinyl 5 3-pyridinyl , and 4-pyridinyl wherein each R2 is substituted by one or two R12. In a further embodiment of compounds of the present invention R" is 3-pyridinyl substituted by one or t In another embodiment of compounds of the present invention R2 is 3-pyridinyl substituted by -S(Oi)NR9R10 )Rn . In a further embodiment of compounds of the present invention R is 3-pyridinyl substituted by -S(02)N(CH3)2 or -S(02)CH3 [0060] In one embodiment of compounds of the present invention R2 is substituted by one R12. In another embodiment of compounds of the present invention R2 is substituted by two R12. In another embodiment of compounds of the present invention R2 is substituted by one or two R12. In a further embodiment of compounds of the present invention R2 is substituted by three R12. In another embodiment of compounds of the present invention R2 is substituted by four or five R . [0061] In one embodiment of compounds of the present invention R3, R4, R3 and R6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, Ci_6alkyl, C3-7cycloalkyl, -0-C1-6alkyl, -0-C3.7cycloalkyl, -CN, -N02, -NR9R10, -C(0)OR8, -C(0)NR9R10, -NR'C(0)RH , -S(02)NR9R10, -NR9S(02)Rn, -S(0)Rn, -S(02)Rn , tetrazole and oxadiazole; wherein each d_6alkyl is a straight or branched chain alkyl; and wherein each Ci_fialkyl and C3_7cycloalkyI is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-C].3alkyl, -CF3, -CH2CF3, and -0-CF3. In another embodiment of compounds of the present invention R3, R4, R3 and R6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C ^alkyl, C3.7cycIoalkyl, -O-C^alkyl, -0-C3.7cycloalkyl, -CN, - N02, -NR9R10, -C(0)OR8, -C(0)NR9R10, -NR9C(0)Ru , -S(02)NR9R1(), -NR9S(02)Rn, -S(0)Rn , -S(02)Rn ; wherein each C^alkyl is a straight or branched chain alkyl; and wherein each Ci_f)alkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH and -0-C].3alkyl. In a further embodiment of compounds of the present invention R3, R4, 3 and R6 are each independently selected from the group consisting of hydrogen, fluoro, chloro, hydroxyl, methyl, cyclopropyl, -CN, -NOz, -NH2, -C(0)OH, -C(0)OMe, -C(0)0Et, -C(0)NR9RK), -S(02)NR9R10, -NR9S(02)Ru, -S(0)Ru , -S(02)Rn, tetrazole, oxadiazole, -CH2F, -CHF2, -OCF3, -CH2OCH3, -CF3, -CHF2CH3, -C(CH3)2OH. [0062] In one embodiment of compounds of the present invention each R7 is independently selected from the group consisting of hydrogen, hydroxyl and Cj_3alkyl. In another embodiment of compounds of the present invention each R7 is selected from the group consisting of hydrogen and hydroxyl. In another embodiment of compounds of the present invention each R7 is selected from the group consisting of hydrogen, hydroxyl and methyl. In a further embodiment of compounds of the present invention each R7 is hydrogen. In another embodiment of compounds of the present invention each R7 is hydroxyl. [0063] In one embodiment of compounds of the present invention R8 is selected from the group consisting of hydrogen, C].6alkyl and C3_7cycloalkyl; wherein each d_6alkyl is a straight or branched chain alkyl; and wherein each Chalky 1 and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -d.^alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -O-CF5. In another embodiment of compounds of the present invention R8 is hydrogen. In a further embodiment of compounds of the present invention R8 is CV6alkyl or C3_7cycloalkyl. In a still further embodiment of compounds of the present invention R8 is hydrogen or C].6alkyl. In another embodiment of compounds of the present invention R8 is Ci_6alkyl. In another embodiment of compounds of the present invention R8 is Ci_3alkyl. In a further embodiment of compounds of the present invention R8 is methyl or ethyl. In another embodiment of compounds of the present invention R8 is selected from the group consisting of hydrogen, methyl and ethyl. [ 0064] In one embodiment of compounds of the present invention R9 and R10 are independently selected from the group consisting of hydrogen, Ci.6alkyl and C3.7cycloalkyl; wherein each Chalky! is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C].3alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -0-CF3. In another embodiment of compounds of the present invention R9 and R10 arc independently selected from the group consisting of hydrogen, Ci_6alkyl and C3_7cycloalkyl. In another embodiment of compounds of the present invention R9 and R10 are independently selected from the group consisting of hydrogen and C^alkyl. In another embodiment of compounds of the present invention R9 and R10 are hydrogen. In a further embodiment of compounds of the present invention R9 and R ° are Ci_6alkyl. In another embodiment of compounds of the present invention R9 and R10 are both methyl. In a further embodiment of compounds of the present invention R9 and R10 are independently selected from the group consisting of hydrogen and C3.7cycloalkyl. In another embodiment of compounds of the present invention R9 is hydrogen and R10 is Ci_6alkyl. In one embodiment of compounds of the present invention R9 is hydrogen and R10 is methyl or isopropyl. In a further embodiment of compounds of the present invention R9 is methyl and R10 is isopropyl. [0065] In one embodiment of compounds of the present invention R9 and R10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members. In another embodiment R9 and R10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 1 additional heteroatoms as ring members. In a further embodiment R9 and R10 when attached to the same nitrogen atom are combined to fonn a 3- to 7-membered ring having 1 additional heteroatom as ring members. In another embodiment R9 and R10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having 0 additional heteroatoms as ring members. [0066] In one embodiment of compounds of the present invention RN is selected from the group consisting of Ci_6alkyl and C3_7cycloalkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -0-CF3. In another embodiment of compounds of the present invention R1 1 is selected from the group consisting of Cj.6alkyl and C3_7cycloalkyl. In another embodiment of compounds of the present invention RU is Chalky!. In a further embodiment of compounds of the present invention R11 is selected from the group consisting of methyl, ethyl and isopropyl. In another embodiment of compounds of the present invention R1 1 is selected from the group consisting of methyl and isopropyl. In a further embodiment of compounds of the present invention R1 1 is C3_7cycloalkyl. In another embodiment of compounds of the present invention R1 1 is cyclopropyl. [0067] In one embodiment of compounds of the present invention R12 is selected from the group consisting of halogen, d_6alkyl, -0-Ci_6alkyl, -S-Ci_6alkyl, C3.7cycloalkyl, -0-C3.7cyeloalkyl, -C(0)OR8, -C(0)NR9R1 0, -NR9C(0)R1 1 , -S(02)NR9R10, -NR9S(02)RU, -S(0)RN and -S(02)RN ; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -Ci_3alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -0-CF3. In a further embodiment of compounds of the present invention R12 is selected from the group consisting of halogen, -0-Ci_6alkyl, -S-CV6alkyl, C3_7cycloalkyl, -0-C3.7cycloalkyl, -C(0)0R8, -C(0)NR9R10, -NR9C(0)R" , -S(02)NR9R' °, -NR9S(02)RU, -S(0)R" and -S(02)RN In another embodiment of compounds of the present invention R12 is selected from the group consisting of halogen, C,_6alkyl, -0-Ci_6alkyl, -S-C^alkyl, -C(0)OR8, -C(0)NR9R1 0, -S(02)NR9R10 -NR9S(02)R" and -S(02)R" . In a further embodiment of compounds of the present invention R is selected from the group consisting of -S(02)NR9R'0 and -S(02)RH. In another embodiment of compounds of the present invention R12 is -S(02)NR9R10. In a further embodiment of compounds of the present invention R12 is -S(02)N(CH3)2. In another embodiment of compounds of the present invention R12 is -S(02)Rn. In a further embodiment of compounds of the present invention R12 is -S(02)CH3. In another embodiment of compounds of the present invention R12 is -S(02)1Pr. [0068] In one embodiment the present invention also relates to compounds of Formula la: Formula la or a pharmaceutically acceptable salt, solvate or prodrug thereof; wherein: X is 0 or -(CHR7)M- m is 1 or 2; R1 is selected from the group consisting of hydrogen, halogen, CV6alkyl, C3_7cycloalkyl, -O-CVealkyl, -0-C3.7cycloalkyl, -C(0)OR8, -C(0)NR9RH) and -NR9C(0)RU ; wherein each CV6alkyl is a straight or branched chain alkyl; and wherein each d_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C^alkyl, -O-Cjjalkyl, -CF3, -CH2CF3, and -0-CF3; R2 is aryl or heteroaryl; wherein each R2 is optionally substituted by one or more R 12; R3, R4, R5 and R6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, Ci_6alkyl, C3.7cycloalkyl, -0-Ci_6alkyl, -0-C3.7cycloalkyl, -CN, -N02, -NR9R10, -C(0)OR8, -C(0)NR9RL°, -NR9C(0)RN, -S(02)NR9R10, -NR9S(02)R", -S(0)RU , -S(02)RN, tetrazole and oxadiazole; wherein each C i_6alkyl is a straight or branched chain alkyl; and wherein each and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci-3alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -0-CF3; each R7 is independently selected from the group consisting of hydrogen, hydroxyl and Ci_3alkyl; R8 is selected from the group consisting of hydrogen, d_6alkyl, and C3_7cycloalkyl; wherein each Cj.6alkyl is a straight or branched chain alkyl; and wherein each C^alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C,_3alkyl, -O-C^alkyl, -CF3, -CH2CF,, and -0-CF3; R9 and R1() are independently selected from the group consisting of hydrogen, C]-6alkyl and C _7cycloalkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-C alkyl, -CF3, -CH2CF3, and -0-CF3; or R9 and R10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members; R1' is selected from the group consisting of Ci_6alkyl and C3_7cycloalkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each C^alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -Cj.,alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3; and R12 is selected from the group consisting of halogen, Ci_6alkyl, -0-Ci_6alkyl, -S-C1-6alkyI, C3.7cycloalkyl, -0-C3.7cycloalkyl, -C(0)OR8, -C(0)NR9R10, -NR9C(0)Ru , -S(02)NR9R1(), -NR9S(02)Rn, -S(0)Ru and -S(02)RH; wherein each C,.6alkyl is a straight or branched chain alkyl; and wherein each C].6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -Ci_3alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3. [0069] In one embodiment of compounds of Formula la of the invention X is CH2; R1 is hydrogen, methyl or -C(0)NR9R10; R2 is phenyl optionally substituted by -S(02)NR9R10; and R\ R4, R5 and R6 are independently selected from the group consisting of hydrogen, C(0)OR8, -C(0) R9R10 and -S(02)NR9RH). [0070] In another embodiment the present invention also relates to compounds of Formula lb: Formula lb or a pharmaceutically acceptable salt, solvate or prodrug thereof; wherein: X is 0 or -(CHR7)m- m is 1 or 2; R1 is selected from the group consisting of hydrogen, halogen, Chalky 1, C3_7cycloalkyl, -O-C^alkyl, -0-C3.7cycloalkyl, -C(0)OR8, -C(0)NR9R, () and -NR9C(0)R" ; wherein each Chalky! is a straight or branched chain alkyl; and wherein each d_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C1-3alkyl, -0-C1-3alkyl, -CF3, -CH2CF3, and -0-CF3; R2 is aryl or heteroaryl; wherein each R2 is optionally substituted by one or more R12; R3, R4 and R 5 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C1-6alkyl, C3.7cycloalkyl, -0-C].6alkyl, -S-CI -5alkyl, -0-C3_7cycloalkyl, -CN, -NO,, -NR9R10, -C(0)OR8, -C(0)NR9R10, -NR9C(0)Ru, -S(02)NR9R10, -NR9S(02)Rn, -S(0)Ru , -S(02)Rn, tetrazole and oxadiazole; wherein each C i_6alkyl is a straight or branched chain alkyl; and wherein each Cj.6alkyl and C3_7Cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -0-CF3; each R' is independently selected from the group consisting of hydrogen, hydroxyl and C^alkyl; R8 is selected from the group consisting of hydrogen, Ci_6alkyl, and C3.7cycloalkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each C^alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-Cj.3alkyl, -CF3, -CH2CF3, and -0-CF3; R9 and R10 are independently selected from the group consisting of hydrogen, C]_6alkyl and C3.7cycloalkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each Chalky! and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C^alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3; or R9 and RI() when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members; Rn is selected from the group consisting of C^alkyl and C3.7cycloaIkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each C i_6alkyl and C .7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -Ci.3alkyl, -0-C1-3alkyl, -CF3, -CH2CF3, and -0-CF3; and R12 is selected from the group consisting of halogen, C i_6alkyl, -0-Ci_6alkyl, -S-C^alkyl, C3-7cycIoalkyl, -0-C3-7cycloalkyl, -C(0)OR8, -C(0)NR9R10, -NR9C(0)Ru , -S(02)NR9R10, -NR S(02)R' \ -S(0)Rn and -S(02)Ru; wherein each C,.6alkyl is a straight or branched chain alkyl; and wherein each Chalky! and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C^alkyl, -O-Ci-jalkyl, -CF3, -CH2CF3, and -0-CF3. [0071] In one embodiment of compounds of Formula lb of the invention m is 1 or 2; R1 is hydrogen, methyl, chlorine, isopropyl, 1 -hydroxyethyl, 2-hydroxyisopropyl; R2 is phenyl or 3-pyridy] optionally substituted by one or more R12; R3, R4 and R5 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, Ci_6alkyl, cyclopropyl, -0-C].6alkyl, -NR'R10, -C(0)OR8 and -C(0)NR9RK); wherein each Chalky! is a straight or branched chain alkyl; and wherein each Chalky! and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen and -OH; and R12 is selected from the group consisting selected from the group consisting of halogen, -S-C]-6alkyl, -S(02)NR9R10, -S(0)Rn and -S(02)Rn. [0072] In a further embodiment of compounds of Fonnula lb of the invention m is 1 or 2; R1 is hydrogen, methyl, chlorine, isopropyl, 1 -hydroxyethyl, 2-hydroxyisopropyl; R2 is phenyl or 3-pyridyl optionally substituted by one or more R12; R3, R4 and 3 are each independently selected from the group consisting of hydrogen, fluorine, chlorine, hydroxyl, methyl, cyclopropyl, -OCH3, -CF3, -CH2F, -CHF2CH3, -CH2OCH3, -C(CH3)2OH, -N(CH3)2, -C(0)OH, -C(0)OEt, -C(0)NHCHj, -C(0)N(CH3)2, -C(0)NH1Pr; R7 is hydrogen or hydroxyl; and R12 is selected from the group consisting selected from the group consisting of chlorine, -S-CH3, -S(02)N(CH )2 -S(02)CH3, -S(02)Et, -S(02)'Pr and -S(02)cyclopropyl. [0073] In another embodiment the present invention also relates to compounds of Formula Ic: Formula Ic or a pharmaceutically acceptable salt, solvate or prodrug thereof; wherein: X is O or -(CHR')m- m is 1 or 2; R1 is selected from the group consisting of hydrogen, halogen, d_6alkyl, C3_7cycloalkyl, -0-Ci-6alkyl, -0-C3_7cycloalkyl, -C(0)OR8, -C(0)NR9R1() and -NR9C(0)Rn; wherein each C^alkyl is a straight or branched chain alkyl; and wherein each C^alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C,-3alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3; R2 is aryl or heteroaryl; wherein each R2 is optionally substituted by one or more R12; R3, R4 and R6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C,.6alkyl, C3.7cycloa.kyl, -0-C ,.5alkyl, -0-C3.7cycloalkyl, -CN, -N02, -NR9Rl°, -C(0)OR8, -C(0)NR9RU), -NR9C(0)Rn, -S(02)NR9R10, -NR9S(02)Rn, -SCO 1 1, -S(02)R1 1, tetrazole and oxadiazole; wherein each Ct_6alkyl is a straight or branched chain alkyl; and wrherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C].3alkyl, -0-C _3alkyl, -CF3, -CH2CF3, and -0-CF3; each R7 is independently selected from the group consisting of hydrogen, hydroxyl and Ci_3alkyl; R8 is selected from the group consisting of hydrogen, d_6alkyl, and C3.7cycloalkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each Ci.6alkyl and C3 7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C^alkyl, -0-C1-3alkyl, -CF3, -CH2CF3, and -0-CF3; R9 and RH) are independently selected from the group consisting of hydrogen, Ci_6alkyl and C3.7cycloalkyl; wherein each C]_6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -0-CF3; or R9 and R10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members; Rn is selected from the group consisting of Ci_6alkyl and C3.7cycloalkyl; wherein each C ealkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -Cj_3alkyl, -0-CV3alkyl, -CF3, -CH2CF3, and -0-CF3; and R12 is selected from the group consisting of halogen, C ].6alkyl, -O-C^alkyl, -S-C] .6alkyl, C3.7cycloalkyl, -0-C3_7cycloalkyl, -C(0)OR8, -C(0)NR9R10, -NR9C(0)RH, -S(02)NR9R10, -NR S(02)Rn, -S(0)Ru and -S(02)RH; wherein each C,.6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -Ci_3alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3. [0074] In one embodiment of compounds of Formula Ic of the invention X is CH2; R1 is methyl, R2 is phenyl optionally substituted by S(02)N(CH3)2 or -S(02)CH3; and R3, R4 and R6 are independently selected from the group consisting of hydrogen and methyl. [0075J In another embodiment the present invention also relates to compounds of Formula Id: Formula Id or a pharmaceutically acceptable salt, solvate or prodrug thereof; wherein: X is 0 or -(CHR7)m- m is 1 or 2; R1 is selected from the group consisting of hydrogen, halogen, Ci_6alkyl, C3.7cycIoalkyl, -O-C^alkyl, -0-C3_7cycloalkyl, -C(0)OR8, -C(0)NR9R1() and -NR9C(0)Rn; wherein each Ci ^alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C.jalkyl, -0-C].3alkyl, -CF3, -CH2CF3, and -0-CF3; R2 is aryl or heteroaryl; wherein each R2 is optionally substituted by one or more R12; R3, R5 and R5 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, d.ealkyl, C3.7cycloalkyl, -0-C,.5alkyl, -0-C3.7cycloalkyl, -CN, -N02, -NR9R10, -C(0)OR8, -C(0)NR9R10, -NR9C(0)Rn, -S(02)NR9R10, -NR9S(02)Ru, -S(0)R11, -S(02)RH, tetrazole and oxadiazole; wherein each d_6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -0-CF3; each R' is independently selected from the group consisting of hydrogen, hydroxyl and C1-3alkyl; R8 is selected from the group consisting of hydrogen, d_6alkyl, and C3_7cycloalkyl; wherein each Cj_6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-Ci_ alkyl, -CF3, -CH2CF3, and -0-CF3; R9 and R10 are independently selected from the group consisting of hydrogen, C]-6alkyl and C3_7cycloalkyl; wherein each Chalk 1 is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C,_3alkyl, -0-CK alkyl, -CF3, -CH2CF3, and -0-CF3; or R9 and R10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members; R11 is selected from the group consisting of Ci_6alkyl and C3_7cycloalkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -Cj.3alkyl, -0-C1-3alkyI, -CF3, -CH2CF3, and -0-CF3; and R12 is selected from the group consisting of halogen, C^alkyl, -0-Ci_6alkyl, -S-Ci-ealkyl, C3.7cycloalkyl, -0-C3_7cycloalkyl, -C(0)OR8, -C(0)NR9R10, -NR9C(0)Ru, -S(02)NR9R10, -NR9S(02)Rn, -S(0)Ru and -S(02)RH; wherein each CI -6alkyl is a straight or branched chain alkyl; and wherein each C]-6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -Ci_3alkyl, -O-d.jalkyl, -CF3, -CH2CF3, and -0-CF3. [0076] In another embodiment the present invention also relates to compounds of Formula le: Formula Ie or a pharmaceutically acceptable salt, solvate or prodrug thereof; wherein: X is 0 or -(CHRV m is 1 or 2; R1 is selected from the group consisting of hydrogen, halogen, d_6alkyl, C3_7cycloalkyl, -0-Ci-6alkyl, -0-C3_7cycloalkyl, -C(0)OR8, -C(0)NR9R1() and -NR9C(0)Rn; wherein each C^alkyl is a straight or branched chain alkyl; and wherein each C^alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C,-3alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3; R2 is aryl or heteroaryl; wherein each R2 is optionally substituted by one or more R12; R4, R5 and R6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C,.6alkyl, C3.7cycloa.kyl, -0-C ,.5alkyl, -0-C3.7cycloalkyl, -CN, -N02, -NR9Rl°, -C(0)OR8, -C(0)NR9RU), -NR9C(0)Rn, -S(02)NR9R10, -NR9S(02)Rn, -SCO 1 1, -S(02)R1 1, tetrazole and oxadiazole; wherein each Ct_6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C].3alkyl, -0-C _3alkyl, -CF3, -CH2CF3, and -0-CF3; each R7 is independently selected from the group consisting of hydrogen, hydroxyl and Ci_3alkyl; R8 is selected from the group consisting of hydrogen, d_6alkyl, and C3_7cycloalkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each Ci.6alkyl and C3 7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C^alkyl, -0-C1-3alkyl, -CF3, -CH2CF3, and -0-CF3; R9 and RH) are independently selected from the group consisting of hydrogen, Ci_6alkyl and C3.7cycloalkyl; wherein each C].6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -0-CF3; or R9 and R10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members; Rn is selected from the group consisting of Ci_6alkyl and C3.7cycloalkyl; wherein each C ealkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -Cj_3alkyl, -0-CV3alkyl, -CF3, -CH2CF3, and -0-CF3; and R12 is selected from the group consisting of halogen, C ].6alkyl, -O-C^alkyl, -S-C] .6alkyl, C3.7cycloalkyl, -0-C3.7cycloalkyl, -C(0)OR8, -C(0)NR9R10, -NR9C(0)RH, -S(02)NR9R1(), -NR S(02)Rn, -S(0)Ru and -S(02)RH; wherein each C,.6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C _7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -G_3alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3. [0077] In another embodiment the present invention also relates to compounds of Formula If: Formula If or a pharmaceutically acceptable salt, solvate or prodrug thereof; wherein: X is O or -(CHR7)m- m is 1 or 2; R1 is selected from the group consisting of hydrogen, halogen, Chalky!, C3_7cycloalkyl, -0-C1-6alkyl, -0-C3.7cycloalkyl, -C(0)OR8, -C(0)NR9R1() and -NR9C(0)Rn; wherein each Chalky! is a straight or branched chain alkyl; and wherein each C i_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -CV3alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3; R2 is aryl or heteroaryl; wherein each R2 is optionally substituted by one or more R12; R3 and R4 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C,.6alkyl, C3-7cycloalkyl, -0-C ,.6alkyl, -0-C3.7cycloalkyl, -CN, -N02, -NR9R10, -C(0)OR8, -C(0)NR9RH), -NR9C(0)Rn, -S(02)NR9R10, -NR9S(02)Rn, -S^R1 1 , -S(02)Rn, tetrazole and oxadiazole; wherein each G_6alkyl is a straight or branched chain alkyl; and wherein each Ci_ alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -G_3alkyl, -0-G_3alkyl, -CF3, -CH2CF3, and -0-CF3; each R7 is independently selected from the group consisting of hydrogen, hydroxyl and Ci_3alkyl; R is selected from the group consisting of hydrogen, G_6alkyl, and C3.7cycloalkyl; wherein each Chalky! is a straight or branched chain alkyl; and wherein each C^alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C^alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3; R9 and R10 are independently selected from the group consisting of hydrogen, C]-6alkyl and C3_7cycIoalkyl; wherein each C].6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -0-CF3; or R9 and R10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members; R11 is selected from the group consisting of Ci_f)alkyl and C3.7cycloalkyl; wherein each C^alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C;5.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -Cj.,alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3; and R is selected from the group consisting of halogen, Cj.6alkyl, -O-Q.calkyl, -S-CLsalkyl, C3.7cycloalkyl, -0-C3-7cycloalkyl, -C(0)ORs, -C(0)NR9R10, -NR9C(0)RH, -S(02)NR9R, (), -NR9S(02)R" , -S(0)Ru and -S(02)Rn; wherein each CI 6alkyl is a straight or branched chain alkyl; and wherein each Chalky 1 and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C^alkyl, -0-d_3alkyl, -CF3, -CH2CF3, and -0-CF3. [0078] In one embodiment of compounds of Formula If of the invention R1 is CV6alkyl, X is -(CHR7)m-, R7 is hydrogen, m is 1 , and R2 is aryl, optionally substituted by one or more R12. In another embodiment of compounds of Formula If R1 is methyl, X is CH2, R2 is phenyl substituted by S(02)NR9R1(); R3 is hydrogen and R4 is methyl. [0079] In another embodiment the present invention also relates to compounds of Formula Ig: Formula Ig harmaceutically acceptable salt, solvate or prodrug thereof; wherein: X is O or -(CHR7)m- m is 1 or 2; R1 is selected from the group consisting of hydrogen, halogen, d_6alkyl, C3_7cycloalkyl, -0-Ci-6alkyl, -0-C3_7cycloalkyl, -C(0)OR8, -C(0)NR9R1() and -NR9C(0)Rn; wherein each C^alkyl is a straight or branched chain alkyl; and wherein each C^alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C,-3alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3; R2 is aryl or heteroaryl; wherein each R2 is optionally substituted by one or more R12; R3 and R5 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C,.6alkyl, C3.7cycloa.kyl, -0-C ,.5alkyl, -0-C3.7cycloalkyl, -CN, -N02, -NR9Rl°, -C(0)OR8, -C(0)NR9RU), -NR9C(0)Rn, -S(02)NR9R10, -NR9S(02)Rn, -SCO 1 1, -S(02)R1 1, tetrazole and oxadiazole; wherein each Ct_6alkyl is a straight or branched chain alkyl; and wrherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C].3alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3; each R7 is independently selected from the group consisting of hydrogen, hydroxyl and Ci_3alkyl; R8 is selected from the group consisting of hydrogen, d_6alkyl, and C3_7cycloalkyl; wherein each Ci_6alkyl is a straight or branched chain alkyl; and wherein each Ci.6alkyl and C3 7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C^alkyl, -0-C1-3alkyl, -CF3, -CH2CF3, and -0-CF3; R9 and RH) are independently selected from the group consisting of hydrogen, Ci_6alkyl and C3.7cycloalkyl; wherein each C].6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3_7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -Ci_3alkyl, -0-Ci_3alkyl, -CF3, -CH2CF3, and -0-CF3; or R9 and R10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members; Rn is selected from the group consisting of Ci_6alkyl and C3.7cycloalkyl; wherein each C ealkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C3.7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -Cj_3alkyl, -0-CV3alkyl, -CF3, -CH2CF3, and -0-CF3; and R12 is selected from the group consisting of halogen, C ].6alkyl, -O-C^alkyl, -S-C] .6alkyl, C3.7cycloalkyl, -0-C3_7cycloalkyl, -C(0)OR8, -C(0)NR9R10, -NR9C(0)RH, -S(02)NR9R10, -NR9S(02)Rn, -S(0)Ru and -S(02)RH; wherein each C,.6alkyl is a straight or branched chain alkyl; and wherein each Ci_6alkyl and C _7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -Ci_3alkyl, -O-C^alkyl, -CF3, -CH2CF3, and -0-CF3. [0080] In one embodiment of compounds of Formula Ig of the i ention R1 is Ci_6alkyl, X is - (CHR7)m-, R7 is hydrogen, m is 1, and R^ is aryl, optionally substituted by one or more R12. In another embodiment of compounds of Formula Ig R1 is methyl, X is CH2, R2 is phenyl substituted by S(02)N(CH3)2 or S(02)CH3; R3 is hydrogen and R5 is methyl. [0081 ] In the context of the present disclosure, any one or more aspect(s) or embodimcnt(s) may be combined with any other aspect(s) or embodiment(s). [0082] Exemplary compounds according to the present invention include the compounds set forth in Table 1 : Table 1 - 1 - - (Z)-3-fluoro-4-(2-methyl-3-((6-(methylsulfonyl)pyridin-3-yl)methyl)-5-(trifluoromethyl)-lH-pyrrolo[3,2-b]pyridin-l -yl)but-2-en- l -amine (Z)-4-(( 1 -(4-amino-2-fluorobut-2-en-l -y l)-2-methyl - lH-pyrrolo [ 3 ,2-c] pyridin- 3 -yl)me thyl ) -N N-dimethylbenzenesulfonamide (Z)-3-fluoro-4-(2-isopropyl-3-(4-(methylsulfonyl)benzyl)-l H-pyrrolo [3 ,2-b jpyridin- 1 -yl)but-2-en- 1 -amine (Z)-3-fluoro-4-(2-methyl-3-(2-methyl-4-(methyIsulfonyl)benzyI)- 1 H-pyrrolo [3 ,2-b jpyridin- 1 -yl)but-2-en- 1 -amine (Z)-4-(3-(3-chloro-4-(methyl su lfonyl)benzyl )-2 -methyl- 1 H-pyrrolo[3,2-b]pyridin- 1 -yl)-3-fIuorobut-2-en- 1 -amine (Z)-4-(2,6-dimethyl-3-(4- (methylsulfonyl)benzyl)-lH- pyrrolo[3,2-c]pyridin-l-yl)-3- fluorobut-2-en- 1 -amine (Z)-4-((5-(4-amino-2-fluorobut-2-en-l - yl)-3,6-dtmethyl-5H-pyrrolo[3,2- c] pyridazin-7-yl)methyl) -N, N- dimethylbenzenesulfonamide (Z)-4-(2,6-dimethyl-7-(4- (methylsulfonyl)benzyl)-5/ - pyrro lo [ 3 , 2-d ] pyr imidin-5 -y] ) -3 - fluorobut-2-en- 1 -amine (Z)-4-((5-(4-amino-2-fluorobut-2-en-l - yl)-2,6-dimethyl-5H-pyrroIo[3,2- d ]pyrimidin-7-yl)methyl)-